Dr. Michael Rybak Joins Ceragenix's Scientific Advisory Board

DENVER, Jan. 31, 2007 -- Ceragenix Pharmaceuticals, Inc. (CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced Michael J. Rybak, PharmD, MPH, FCCP, FIDSA, has joined its scientific advisory board.

Dr. Rybak is the associate dean for research and professor of pharmacy at the Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), and an adjunct professor of medicine in the Division of Infectious Diseases at the School of Medicine at Wayne State University in Detroit, Michigan. Dr. Rybak also serves as the director of the Anti-Infective Research Laboratory at the EACPHS, and is affiliated with Detroit Receiving Hospital and University Health Center. He received his B.S. in Pharmacy from Northeastern University, PharmD from the College of Pharmacy and Health Sciences, and MPH from the School of Medicine at Wayne State University.

Important to Ceragenix's developing line of anti-infectives, Dr. Rybak's primary research focus is antimicrobial pharmacokinetics and pharmacodynamics and their relationship to bacterial resistance. He has published more than 200 manuscripts, book chapters, and review articles in scientific journals on topics that included antimicrobial PK/PD and resistance to antimicrobial agents, the importance of bactericidal drugs, and the assessment of patient outcome as it relates to antimicrobial resistance issues.

He is a member of several professional societies, including the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, the Society of Infectious Diseases Pharmacists, the American Society for Microbiology, and the Infectious Diseases Society of America. He is also a fellow of both the American College of Pharmacy and the Infectious Diseases Society of America. Dr. Rybak serves as the scientific field editor for the infectious diseases section of Pharmacotherapy, as well as an editorial reviewer for a number of other scientific publications.

"We are fortunate and honored to have Dr. Rybak join our scientific advisory board," said Steven Porter, chairman and chief executive officer of Ceragenix. "We will benefit from his expert advice and years of experience in the field of infectious diseases and anti-infective research."

Rybak joins a number of other esteemed scholars and researchers on the Ceragenix scientific advisory board, which includes Dr. Peter Elias of UCSF, Dr. Henry F. Chambers of San Francisco General Hospital, Dr. Tomas Ganz of UCLA, Dr. Richard Gallo of UCSD, Dr. Donald Y. Leung of the National Jewish Medical Center, and Professor Sean Gorman of Queens University, Belfast, UK.

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram(TM) and NeoCeram(TM). For additional information on Ceragenix, please visit www.ceragenix.com.

Contacts: Ceragenix Pharmaceuticals, Inc.
          Steven S. Porter, Chief Executive Officer
          720-946-6440
             or
          Liolios Group, Inc. 
          Investor Relations 
          Ron Both 
          949-574-3860
          ron@liolios.com